Keywords: GW Pharmaceuticals, Type 2 diabetes, Cannabinoids, Metabolic syndrome

GW Pharma initiates Ph IIa study of cannabinoid in diabetes

Article | 01 October 2010

Print This

UK-based GW Pharmaceuticals (GWP: AIM) has commenced the first of a program of Phase IIa exploratory clinical trials exploring its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in